Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
bioLytical Laboratories
Richmond, British Columbia, Canada
- Ownership
- Private
- Employees
- ~90
- Development stage
- Other
01
Overview
bioLytical Laboratories commercializes rapid, point-of-care diagnostic tests for infectious diseases—most notably the INSTI HIV-1/2 test, capable of providing results in as little as 60 seconds with >99% sensitivity and specificity, along with hepatitis C and syphilis tests, among others. Their products are globally approved (including FDA, Health Canada, CE) and widely used, with more than 35 million people tested to date[1][4][11][14].
- Therapeutic areas
- Infectious Diseases
- Modalities
- DeviceIn vitro diagnosticAntibodyAntigen
- Industry
- Protein Biomarker Diagnostics
Beyond the preview
Go deeper on bioLytical Laboratories.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bioLytical Laboratories.